Thursday, October 4, 2012

Pfizer denied patent for Sutent (sunitinib) in India

Sutent which is a preferred treatment for first line advanced renal cell carcinoma globally has been denied patent in India.  Cipla and a few other local drug makers, including Natco Pharma limited  had opposed the Indian patent for Sutent. The patent was denied on the grounds that the patent lacked an inventive step and was obvious.